ChemoCentryx, Inc. $346.8 Million Follow-On Offering

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which included 780,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares), for total gross proceeds of approximately $346.8 million. ChemoCentryx’s common stock is listed on the Nasdaq Global Select Market under the symbol “CCXI.”

ChemoCentryx is a biopharmaceutical company focused on the development and commercialization of new medications targeted at inflammatory disorders, autoimmune diseases and cancer.

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Bryan M. Quinn, Blake Anderson and Sylvia Zaich. The tax team included counsel Ethan R. Goldman. The intellectual property and technology transactions team included partner Frank J. Azzopardi and associates Mikaela Dealissia and Jessica Brodman. Members of the Davis Polk team are based in the Northern California and New York offices.